文献速递肾癌与肾肿瘤

尿液蛋白用于肾癌早期检测:一种真正无创的策略

Early detection of kidney cancer using urinary proteins: a truly non-invasive strategy.
PubMed 文献 · BJU Int · 2021-11-03

本文综述了尿液蛋白生物标志物作为肾细胞癌(RCC)无创早期诊断工具的潜力。通过检索PubMed截至2020年的原始研究,发现多种尿液蛋白标志物(如aquaporin-1、perilipin-2等)正在验证中,但尚无标志物因敏感性或特异性低、研究设计不一致或缺乏外部验证而获批临床使用。结论认为评估标志物可行性、样本处理与储存、验证及新技术应用可能最大化早期RCC无创诊断的潜力。

要点

  • 多种尿液蛋白标志物正在验证用于RCC诊断,但尚无获批临床使用。
  • 现有标志物因敏感性或特异性低、研究设计不一致或缺乏外部验证而未达临床要求。
  • 优化标志物可行性、样本处理与储存、验证及新技术应用可能推动无创诊断。

核心结论

  • 尿液蛋白生物标志物在早期RCC诊断中具有潜力,但尚无标志物被验证或批准用于临床。

研究设计与样本

  • 综述:检索PubMed数据库截至2020年的原始研究,识别报道RCC潜在尿液蛋白标志物的研究。

主要发现

  • 多种尿液蛋白标志物正在验证用于RCC诊断,包括aquaporin-1、perilipin-2、carbonic anhydrase-9、Raf-kinase inhibitory protein、nuclear matrix protein-22、14-3-3 Protein β/α和neutrophil gelatinase-associated lipocalin。
  • 尚无标志物被验证或批准用于临床使用,原因包括敏感性或特异性低、研究设计不一致或缺乏外部验证。

关键数值与推荐

  • 无关键数值与推荐(综述未报告具体阈值或推荐条款)。

临床怎么用

  • 目前尿液蛋白标志物尚不能用于临床RCC早期诊断,需进一步验证。

局限性

  • 综述未报告具体样本量、敏感性/特异性数值或外部验证结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To review urinary protein biomarkers as potential non-invasive, easily obtainable, early diagnostic tools in renal cell carcinoma (RCC). METHODS: A PubMed database search was performed up to the year 2020 to identify primary studies reporting potential urinary protein biomarkers for RCC. Separate searches were conducted to identify studies describing appropriate methods of developing cancer screening programmes and detection of cancer biomarkers. RESULTS: Several urinary protein biomarkers are under validation for RCC diagnostics, e.g. aquaporin-1, perilipin-2, carbonic anhydrase-9, Raf-kinase inhibitory protein, nuclear matrix protein-22, 14-3-3 Protein β/α and neutrophil gelatinase-associated lipocalin. However, none has yet been validated or approved for clinical use due to low sensitivity or specificity, inconsistencies in appropriate study design, or lack of external validation. CONCLUSIONS: Evaluation of biomarkers' feasibility, sample preparation and storage, biomarker validation, and the application of novel technologies may provide a solution that maximises the potential for a truly non-invasive biomarker in early RCC diagnostics.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Flitcroft JG, Verheyen J, Vemulkar T, et al. Early detection of kidney cancer using urinary proteins: a truly non-invasive strategy. BJU Int. 2021. PMID: 34570419. doi:10.1111/bju.15601

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。